EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors

Yeonjoo Choi, Jiayi Tan iD, David Lin, Jin Sun Lee iD, Yuan Yuan iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26083920 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yeonjoo Choi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA. Hauptthemen laut MEDLINE: Immune Checkpoint Inhibitors, Immunotherapy, Breast Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 140 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The systemic treatment of breast cancer has evolved remarkably over the past decades. With the introduction of immune checkpoint inhibitors (ICIs), clinical outcomes for solid tumor malignancies have significantly improved. However, in breast cancer, the indication for ICIs is currently limited to triple-negative breast cancer (TNBC) only. In high-risk luminal B hormone receptor-positive (HR+) breast cancer (BC) and HER2-positive (HER2+) BC, modest efficacy of ICI and chemotherapy combinations were identified in the neoadjuvant setting. To address the unmet need, several novel immunotherapy strategies are being tested in ongoing clinical trials as summarized in the current review: bispecific antibodies, chimeric antigen receptor T-cell therapy (CAR-T), T-cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs), tumor vaccines, and oncolytic virus therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immune Checkpoint InhibitorsImmunotherapyBreast NeoplasmsHumansFemaleCancer VaccinesLymphocytes, Tumor-InfiltratingAntibodies, BispecificOncolytic VirotherapyImmunotherapy, Adoptive

Stichwörter der Autor:innen

bispecific antibodybreast cancercancer vaccinecell-based therapyimmunotherapyoncolytic virus

Substanzen

Immune Checkpoint InhibitorsCancer VaccinesAntibodies, Bispecific

Autor:innen und Institutionen

  • Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA.

ORCID-Profile: Jiayi Tan, Jin Sun Lee, Yuan Yuan

Zitieren

APA

Choi, Y., Tan, J., Lin, D., Lee, J. S., & Yuan, Y. (2025). Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26083920

Vancouver

Choi Y, Tan J, Lin D, Lee JS, Yuan Y. Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26083920

BibTeX
@article{Choi2025,
  author = {Choi, Yeonjoo and Tan, Jiayi and Lin, David and Lee, Jin Sun and Yuan, Yuan},
  title = {Immunotherapy in Breast Cancer: Beyond Immune Checkpoint Inhibitors},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26083920}
}
Kostenlos starten →